Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Kymera Therapeutics Inc
(NQ:
KYMR
)
44.98
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Kymera Therapeutics Inc
< Previous
1
2
3
4
Next >
The Latest Analyst Ratings For Kymera Therapeutics
November 01, 2024
Via
Benzinga
Preview: Kymera Therapeutics's Earnings
October 30, 2024
Via
Benzinga
Insights Ahead: Kymera Therapeutics's Quarterly Earnings
October 30, 2024
Via
Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Novartis aims to enhance Pluvicto's market presence while exploring growth in multiple sclerosis and expanding its radioligand therapy portfolio.
Via
Benzinga
The Analyst Landscape: 7 Takes On Kymera Therapeutics
September 27, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
September 09, 2024
Via
Benzinga
Unveiling 6 Analyst Insights On Kymera Therapeutics
August 12, 2024
Via
Benzinga
Why Kymera Therapeutics Stock Is Soaring Today
July 09, 2024
Kymera's lead pipeline candidate received some good news.
Via
The Motley Fool
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
June 17, 2024
Via
Benzinga
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
May 24, 2024
Via
Benzinga
This BJ's Wholesale Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
August 26, 2024
Via
Benzinga
XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details
July 14, 2024
10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit...
Via
Benzinga
Why Helen of Troy Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 09, 2024
Via
Benzinga
Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
April 22, 2024
Via
Benzinga
Breaking Down Kymera Therapeutics: 4 Analysts Share Their Views
February 23, 2024
Via
Benzinga
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (4 Ratings)
December 19, 2023
Via
Benzinga
Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday
July 09, 2024
Via
Benzinga
KYMR Stock Earnings: Kymera Therapeutics Beats EPS, Misses Revenue for Q1 2024
May 02, 2024
KYMR stock results show that Kymera Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Via
InvestorPlace
Piper Sandler Maintains Overweight Rating for Kymera Therapeutics: Here's What You Need To Know
February 27, 2024
Via
Benzinga
Kymera Therapeutics Stock Whiplash: Shares Soar, Then Tumble After $275 Million Offering
January 05, 2024
Shares soared and then tumbled Friday after the company offered $275 million in public shares.
Via
Investor's Business Daily
More Than $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying
November 07, 2023
Although U.S. stocks closed slightly higher on Monday, there were a few notable insider trades.
Via
Benzinga
Preview: Kymera Therapeutics's Earnings
November 01, 2023
Via
Benzinga
The Latest Analyst Ratings for Kymera Therapeutics
August 29, 2023
Via
Benzinga
Expert Ratings for Kymera Therapeutics
August 04, 2023
Via
Benzinga
Earnings Scheduled For February 22, 2024
February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million.
Via
Benzinga
Analyst Expectations for Kymera Therapeutics's Future
November 13, 2023
Via
Benzinga
HC Wainwright & Co. Maintains Buy Rating for Kymera Therapeutics: Here's What You Need To Know
November 03, 2023
Via
Benzinga
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session
October 06, 2023
Gainers
Via
Benzinga
Why Shares of Kymera Therapeutics Jumped on Tuesday
October 03, 2023
The company had a big bounce after hitting a 52-week low the day before.
Via
The Motley Fool
Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday
August 29, 2023
Stifel raised the price target for Hersha Hospitality Trust (NYSE: HT) from $8.75 to $10. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. Hersha Hospitality Trust shares fell 0.5% to...
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.